Hofseth BioCare - Approval of prospectus

Thu Apr 4, 2013 1:30am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:


The Norwegian Financial Supervisory Authority has approved the prospectus dated 3 April 2013 in
connection with the listing of 12,923,496 new shares on Oslo Axess.

The prospectus will be made publicly available at the offices of Hofseth BioCare ASA, Smuget 1,
1383 Asker and telephone: +47 66 76 55 60 or +47 66 76 55 62, or one of the Managers. The
prospectus will also be available on the following websites:

- Hofseth BioCare ASA, www.hofsethbiocare.no
- Swedbank First Securities, www.swedbank.no
- Norne Securities AS, www.norne.no 

For further information, please contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Tel +47 936 32 966
E-mail: joo@h-bc.no

Øystein Omvik, CFO Hofseth BioCare ASA
Tel: +47 936 99 400
E-mail: oystein.omvik@h-bc.no

About Hofseth BioCare:
Hofseth BioCare is a Norwegian biomarine company with the key objective to provide high value
added biomarine ingredients for human applications. The Company is founded on the core value of
sustainability and optimal use of natural resources. Through innovative production technology and
logistics, Hofseth BioCare is able to preserve the quality of protein, calcium and oil extracted
from fish off-cuts. Products that previously could only be used as animal feed can now be made
suitable for human consumption. HBCs objective is thus to contribute to efficient use of marine
resources and entering the higher profit market of quality ingredients for human applications.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the
Norwegian Securities Trading Act.


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Hofseth Biocare ASA via Thomson Reuters ONE